Published in Osteoporos Int on January 01, 1999
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int (2003) 2.19
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int (2003) 2.02
Clinical risk factors as predictors of postmenopausal osteoporosis in general practice. Br J Gen Pract (2001) 1.73
Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int (2008) 1.68
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int (2007) 1.64
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol (2013) 1.44
Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int (2006) 1.41
Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. Calcif Tissue Int (2012) 1.41
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab (2005) 1.34
Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res (2010) 1.19
Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int (2008) 1.14
What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci (2002) 1.14
The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol (2008) 1.13
The impact of a simple fracture clinic intervention in improving the diagnosis and treatment of osteoporosis in fragility fracture patients. Osteoporos Int (2003) 1.13
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
The effect of long-term alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res (2011) 1.10
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int (2003) 1.09
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int (2005) 1.09
A systematic review of the effectiveness of interventions to improve post-fracture investigation and management of patients at risk of osteoporosis. Implement Sci (2010) 1.09
Sex and gender considerations in male patients with osteoporosis. Clin Orthop Relat Res (2011) 1.08
The effect of the microscopic and nanoscale structure on bone fragility. Osteoporos Int (2008) 1.07
Treatment of osteoporosis in men. Bone (2012) 1.06
Bisphosphonates in osteoporosis. Eur Spine J (2003) 1.05
Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab (2007) 1.02
Patients' preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int (2008) 1.02
Femoral stress fractures associated with long-term bisphosphonate treatment. Clin Orthop Relat Res (2012) 1.01
Osteoporosis and skeletal fractures. HSS J (2006) 1.01
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int (2004) 1.00
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord (2011) 0.99
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int (2010) 0.99
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int (2009) 0.97
Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trial. BMC Complement Altern Med (2012) 0.96
Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study. Osteoporos Int (2006) 0.95
Hip fractures in users of first- vs. second-generation bisphosphonates. Osteoporos Int (2007) 0.94
Contralateral hip fractures and other osteoporosis-related fractures in hip fracture patients: incidence and risk factors. An observational cohort study of 1,229 patients. Arch Orthop Trauma Surg (2012) 0.93
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res (2008) 0.92
Hepatotoxicity induced by alendronate therapy. Osteoporos Int (2007) 0.92
Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom (2011) 0.91
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol (2008) 0.90
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface. Osteoporos Int (2008) 0.87
Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab (2012) 0.86
Are osteoporotic fractures being adequately investigated? A questionnaire of GP & orthopaedic surgeons. BMC Fam Pract (2006) 0.85
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken) (2013) 0.85
Treatment of primary osteoporosis in men. Clin Interv Aging (2014) 0.84
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. MedGenMed (2004) 0.84
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging (2012) 0.82
Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab (2014) 0.81
The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Osteoporos Int (2005) 0.81
The implications of a growing evidence base for drug use in elderly patients. Part 4. Vitamin D and bisphosphonates for fractures and osteoporosis. Br J Clin Pharmacol (2006) 0.81
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis (2007) 0.81
Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females. Korean J Intern Med (2013) 0.80
Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study. Eur J Clin Pharmacol (2014) 0.80
If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag (2011) 0.80
Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis (2010) 0.80
Changes in first hip fracture rates in British Columbia Canada, 1990-2004. Osteoporos Int (2011) 0.80
Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. Wien Klin Wochenschr (2006) 0.79
Treatment of osteopenia. Rev Endocr Metab Disord (2012) 0.79
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int (2007) 0.79
Pharmacological treatments for osteoporosis in very elderly people. Ther Adv Chronic Dis (2011) 0.79
Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case-control study. BMC Gastroenterol (2014) 0.78
Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis. J Orthop Surg Res (2007) 0.78
Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. Clin Interv Aging (2009) 0.78
The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging (2007) 0.78
The efficacy and safety of a combined alendronate and calcitriol agent (maxmarvil): a postmarketing surveillance study in korean postmenopausal women with osteoporosis. Korean J Fam Med (2012) 0.78
Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporos Int (2011) 0.78
Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clin Interv Aging (2006) 0.78
Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty. Int Orthop (2005) 0.77
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging (2013) 0.77
Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Alendronate sodium in the management of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf (2011) 0.77
Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int (2004) 0.76
Once-monthly risedronate for postmenopausal osteoporosis. Int J Womens Health (2010) 0.76
Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis. Exp Ther Med (2015) 0.75
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporos Int (2012) 0.75
Risk of severe upper gastrointestinal complications among oral bisphosphonate users. PLoS One (2013) 0.75
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension. Osteoporos Int (2015) 0.75
Effects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study. Korean J Intern Med (2011) 0.75
Association between alendronate and atypical femur fractures: a meta-analysis. Endocr Connect (2014) 0.75
We need a break: Bisphosphonates. J Clin Orthop Trauma (2013) 0.75
Prevention of early bone loss around the prosthesis by administration of anti-osteoporotic agents and influences of collared and non-collared femoral stem prostheses on early periprosthetic bone loss. Eur J Orthop Surg Traumatol (2012) 0.75
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
The reliability of height and height velocity in the assessment of growth (the Wessex Growth Study) Arch Dis Child (1991) 4.15
The reliability of height measurement (the Wessex Growth Study). Arch Dis Child (1990) 4.00
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 3.58
Poor growth in school entrants as an index of organic disease: the Wessex growth study. BMJ (1992) 3.43
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax (2000) 2.74
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Transcription errors in the drug information supplied from hospital to general practitioners. Health Bull (Edinb) (1978) 2.51
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology (2001) 2.29
Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care (2003) 2.22
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med (1996) 2.00
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol (1995) 1.94
Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol (2001) 1.91
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med (1998) 1.84
Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma. Gut (1993) 1.83
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab (2013) 1.77
Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study. Osteoporos Int (2006) 1.75
Acute physiological effects of exhaustive whole-body vibration exercise in man. Clin Physiol (2000) 1.72
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Fatness leads to inactivity, but inactivity does not lead to fatness: a longitudinal study in children (EarlyBird 45). Arch Dis Child (2010) 1.69
How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int (2010) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Parents' awareness of overweight in themselves and their children: cross sectional study within a cohort (EarlyBird 21). BMJ (2004) 1.65
Bone-muscle strength indices for the human lower leg. Bone (2000) 1.65
Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology (1998) 1.64
Do we need new growth charts? Lancet (1987) 1.64
BMI was right all along: taller children really are fatter (implications of making childhood BMI independent of height) EarlyBird 48. Int J Obes (Lond) (2011) 1.62
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract (2009) 1.61
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Reference ranges of bone mineral density for women in southern England: the impact of local data on the diagnosis of osteoporosis. Br J Radiol (1996) 1.55
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. J Musculoskelet Neuronal Interact (2010) 1.53
The European Spine Phantom--a tool for standardization and quality control in spinal bone mineral measurements by DXA and QCT. Eur J Radiol (1995) 1.51
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract (2008) 1.50
Oxygen uptake during whole-body vibration exercise: comparison with squatting as a slow voluntary movement. Eur J Appl Physiol (2001) 1.49
Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol (1998) 1.48
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med (2000) 1.47
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. Breast (2009) 1.47
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int (2014) 1.45
Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) (1985) 1.45
Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res (2001) 1.45
Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet (1985) 1.42
Oxygen uptake in whole-body vibration exercise: influence of vibration frequency, amplitude, and external load. Int J Sports Med (2002) 1.41
Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol (1998) 1.40
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int (2010) 1.34
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (1987) 1.34
Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol (1989) 1.28
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int (2010) 1.27
A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections. Clin Orthop Relat Res (2008) 1.26
Urology in a modern health centre. Br Med J (1975) 1.26
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Osteoporosis changes the amount of vertebral trabecular bone at risk of fracture but not the vertebral load distribution. Spine (Phila Pa 1976) (2001) 1.24
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int (2010) 1.24
Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res (2001) 1.23
Assortative weight gain in mother-daughter and father-son pairs: an emerging source of childhood obesity. Longitudinal study of trios (EarlyBird 43). Int J Obes (Lond) (2009) 1.21
Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol (1985) 1.20
Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int (2001) 1.20
Diphosphonates and phosphate homoeostasis in man. Clin Sci (Lond) (1988) 1.20
Creutzfeldt-Jakob disease presenting as progressive aphasia. J Natl Med Assoc (1985) 1.18
Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int (2010) 1.17
The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study. Osteoporos Int (2001) 1.17
The impact of school-time activity on total physical activity: the activitystat hypothesis (EarlyBird 46). Int J Obes (Lond) (2011) 1.16
Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int (2004) 1.15
Is short vertebral height always an osteoporotic fracture? The Osteoporosis and Ultrasound Study (OPUS). Bone (2007) 1.15
Brain tumors in childhood. Childs Brain (1979) 1.15
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab (1996) 1.15
Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) (1984) 1.14
Differences in ankle joint complex range of motion as a function of age. Foot Ankle (1993) 1.14
Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography. Eur J Radiol (1989) 1.14
Body size accounts for most differences in bone density between Asian and Caucasian women. The EPIC (Early Postmenopausal Interventional Cohort) Study Group. Calcif Tissue Int (1996) 1.13
An immunophenotypic survey of malignant melanomas. Histopathology (1993) 1.13
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int (2011) 1.13
Detailed analyses of periarticular osteoporosis in rheumatoid arthritis. Osteoporos Int (2000) 1.13
Physical activity at the government-recommended level and obesity-related health outcomes: a longitudinal study (Early Bird 37). Arch Dis Child (2008) 1.13
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol (1996) 1.13
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther (2002) 1.12